Lotus Eye Hospital And Institute Limited

CIN No. : L85110TZ1997PLC007783

770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore - 641 014.
Tel : 0422 - 4229900, 4229999

R.S.PURAM
155B, East Periasamy Road, Near Chinthamani,
North Coimbatore, R.S.Puram, Coimbatore - 641 002.
Ph : 0422 - 4239900, 4239999

SARAVANAMPATTI
86/1, Site No.2, TRM Avenue, Sathy Road,
Saravanampatti, Coimbatore - 641 035.
Ph : 0422 - 2210021

E-mail : info@lotuseye.org
Website : www.lotuseye.org

November 21, 2026

BSE Limited **Phiroze Jeejeebhoy Towers** **Dalal Street,** **Mumbai – 400 001** **Scrip Code: 532998**	**National Stock Exchange of India Limited** **Exchange Plaza, C-1, Block G,** **Bandra Kurla Complex,** **Bandra (East), Mumbai – 400 051** **Scrip Code: LOTUSEYE**

Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we enclose herewith the Investor Presentation on the Standalone Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.

This is for your information and records.

Thanking You
For Lotus Eye Hospital and Institute Limited

SENTHILKUMAR PRATHISH

Digitally signed by SENTHILKUMAR PRATHISH
Date: 2026.11.21 18:03:58 +05'30'

Prathish S
Company Secretary & Compliance Officer

LOTUS EYE HOSPITAL & INSTITUTE LIMITED

INVESTOR PRESENTATION

Q2 & H1 ENDED SEPTEMBER 30, 2026
FY 2026–27

www.lotuseye.org

Company at a Glance

Lotus Eye Hospital and Institute Limited is a hi-tech super-specialty eye-care hospital headquartered in Coimbatore, Tamil Nadu, with a presence across Tamil Nadu and Kerala.

HEADQUARTERS

Coimbatore

Tamil Nadu

GEOGRAPHICAL PRESENCE

Tamil Nadu & Kerala

BUSINESS SEGMENT

Eye Care

Single operating segment

LISTED SINCE

2008

CIN: L85110TZ1997PLC007783

CORPORATE PROFILE

Registered Office: 770/12, Avinashi Road, Aerodrome Post, Coimbatore – 641 014

Website: www.lotuseye.org | Email: companysecretary@lotuseye.org

Business Overview

CORE BUSINESS

Eye care related sales and services

The Company reports a single operating segment under Ind AS 108: “Eye Care related sales and services”.

KEY CLINICAL SPECIALITIES / SERVICES

- ✓ Cataract and LASIK
- ✓ Squint and diabetic retinopathy
- ✓ Pediatric ophthalmology and cornea
- ✓ Retina, glaucoma and Oculoplasty
- ✓ Optical services

TECHNOLOGY & CLINICAL CAPABILITIES

- ✓ Advanced ophthalmic diagnostic and surgical equipment
- ✓ Technology-enabled eye care and treatment solutions
- ✓ Comprehensive outpatient and surgical infrastructure
- ✓ Refractive, cataract and retinal care capabilities
- ✓ Integrated clinical support and diagnostic services

PATIENT PROPOSITION / DIFFERENTIATORS

- ✓ Comprehensive eye care services under one roof
- ✓ Established presence across multiple locations
- ✓ Patient-centric approach to clinical care and service delivery
- ✓ Experienced ophthalmologists and healthcare professionals
- ✓ Focus on quality, accessibility and affordability; integrated diagnosis, treatment and post-operative follow-up

Q2 & H1 FY27 – Key Highlights

Q2 REVENUE

₹17.72 Cr

+35.94% YoY

Q2 NET PROFIT

₹43.95 L

Q2 FY26: ₹11.58 lakh

H1 REVENUE

₹34.78 Cr

+30.96% YoY

H1 NET PROFIT

₹1.05 Cr

+59.44% YoY

PROFIT BEFORE TAX

Q2 FY27 **₹55.87 lakh** | Q2 FY26 ₹7.30 lakh


H1 FY27 **₹156.89 lakh** | H1 FY26 ₹80.28 lakh

The Unaudited Results for the quarter and half year ended September 30, 2026 were reviewed by the Audit Committee and approved by the Board on November 11, 2026. The Statutory Auditors conducted a limited review.


Quarterly Financial Performance

₹ crore, except PBT and net profit in ₹ lakh

Revenue



Profitability




Revenue from Operations increased 35.94% year-on-year. PBT was ₹55.87 lakh and Net Profit was ₹43.95 lakh in Q2 FY27.


Half-Yearly Financial Performance

₹ crore, except PBT and net profit in ₹ lakh

Revenue




Profitability



H1 Revenue from Operations grew 30.97% year-on-year. PBT increased 95.43%, while Net Profit increased 59.44%.

Operating Cost Structure

H1 FY27 expenses (₹ lakh)



TOTAL EXPENSES

₹33.72 Cr

H1 FY27

EXPENSE GROWTH

28.62%

Compared with H1 FY26

Balance Sheet Highlights

TOTAL ASSETS

₹100.59 Cr

As at September 30, 2026

TOTAL EQUITY

₹61.21 Cr

As at September 30, 2026

TOTAL BORROWINGS*


₹17.73 Cr

Current + non-current

CASH EQUIVALENTS

₹1.74 Cr

As at September 30, 2026



*Borrowings comprise current and non-current borrowings; lease liabilities are excluded. Figures are based on the statement of assets and liabilities.

Shareholding Pattern

Shareholding Pattern as at September 30, 2026

PROMOTERS & PROMOTER GROUP

40.14%

PUBLIC SHAREHOLDING

59.86%

SHAREHOLDING DISTRIBUTION



Promoters & Promoter Group

Public

EQUITY SHARE CAPITAL

2,07,96,330 shares | Face value: ₹10

Management Team

Kavetha Sundaramoorthy

Chairperson's words

"The ambition and objectives is to actualize and institute an earnest, unrelenting and persisting organization."

Sangeetha Sundaramoorthy

Managing Director's words

"In this aeon for LOTUS, the importance, emphasis and priority, will always be in ensuring and securing the credence and credibility of our shareholders."

Growth Priorities & Strategic Initiatives

EXPANSION PLANS / NEW CENTRES

- ✓ Expand hospital network across existing and new geographies.
- ✓ Strengthen presence in key markets; evaluate new hospitals and satellite centres.
- ✓ Phase expansion based on market potential and business viability.

CLINICAL CAPABILITY / TECHNOLOGY INVESTMENTS

- ✓ Upgrade ophthalmic diagnostic and surgical infrastructure.
- ✓ Adopt advanced technologies in cataract and refractive surgery.
- ✓ Strengthen specialties, equipment, clinical quality and patient outcomes.

OPERATIONAL PRIORITIES / EFFICIENCY INITIATIVES

- ✓ Standardize operating procedures and strengthen resource utilization.
- ✓ Enhance patient experience and digital integration, CRM and engagement.
- ✓ Improve performance monitoring, data-led decisions and cost productivity.

GROWTH OUTLOOK / MANAGEMENT GUIDANCE

- ✓ Pursue sustainable growth and long-term value creation.
- ✓ Strengthen existing centres, network reach, clinical services and capacity utilization.
- ✓ Balance growth, profitability and operational excellence.

KEY OPPORTUNITIES AND RISKS

Growing demand for specialized ophthalmic care; increasing awareness and adoption of advanced treatments; opportunities for geographic expansion and deeper penetration in existing markets; demand for refractive and premium cataract procedures.

Disclaimer

This presentation has been prepared by Lotus Eye Hospital and Institute Limited (the “Company”) solely for informational purposes. It does not constitute an offer, invitation or recommendation to purchase or subscribe to any securities of the Company, nor shall it form the basis of or be relied upon in connection with any contract or binding commitment.

The Company has not scheduled or planned any meeting with investors or analysts in connection with this presentation.

Certain statements may constitute forward-looking statements based on management’s current beliefs, assumptions and expectations. Such statements are subject to risks and uncertainties, and actual results may differ materially. The Company undertakes no obligation to update forward-looking statements, except as required under applicable laws and regulations. The information and opinions are subject to change and should not be relied upon as current beyond the date of this presentation.

This presentation is for general information only and does not take into account any person’s investment objectives or financial circumstances. The Company may modify its contents without prior notice. No part of this presentation may be reproduced or redistributed, except as required under applicable laws or regulations.

Thank You